IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells

Biochemical and Biophysical Research Communications

Volumn 430, Issue 1, 2013, Pages 364-369

  Long, Jun ^a   Zhang, Xulong ^a   Wen, Mingjie ^a   Kong, Qingli ^a   Lv, Zhe ^a   An, Yunqing ^a   Wei, Xiao Qing ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Apoptosis; Cell cycle; Growth; Human cancer; IL 35

Indexed keywords

CYCLIN D1; FAS ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12P35; INTERLEUKIN 35; MESSENGER RNA; PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL STRAIN HEK293; COLON CANCER; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; NEUROBLASTOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CARCINOMA;

ANTIGENS, CD95; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKINS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

HUMAN HERPESVIRUS 4;

EID: 84872407360     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.11.004     Document Type: Article

References (23)

1. Collison L.W., Workman C.J., Kuo T.T., Boyd K., Wang Y., Vignali K.M., Cross R., Sehy D., Blumberg R.S., Vignali D.A. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
2. Chaturvedi V., Collison L.W., Guy C.S., Workman C.J., Vignali D.A. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J. Immunol. 2011, 186:6661-6666.
3. Seyerl M., Kirchberger S., Majdic O., Seipelt J., Jindra C., Schrauf C., Stockl J. Human rhinoviruses induce IL-35-producing Treg via induction of B7-H1 (CD274) and sialoadhesin (CD169) on DC. Eur. J. Immunol. 2010, 40:321-329.
4. Liu F., Tong F., He Y., Liu H. Detectable expression of IL-35 in CD4+ T cells from peripheral blood of chronic hepatitis B patients. Clin. Immunol. 2011, 139:1-5.
5. Bardel E., Larousserie F., Charlot-Rabiega P., Coulomb-L'Hermine A., Devergne O. Human CD4+ CD25+ Foxp3+ regulatory T cells do not constitutively express IL-35. J. Immunol. 2008, 181:6898-6905.
6. Niedbala W., Wei X.Q., Cai B., Hueber A.J., Leung B.P., McInnes I.B., Liew F.Y. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur. J. Immunol. 2007, 37:3021-3029.
7. Kimpfler S., Sevko A., Ring S., Falk C., Osen W., Frank K., Kato M., Mahnke K., Schadendorf D., Umansky V. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J. Immunol. 2009, 183:6330-6337.
8. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010.
9. Matsui M., Kishida T., Nakano H., Yoshimoto K., Shin-Ya M., Shimada T., Nakai S., Imanishi J., Yoshimoto T., Hisa Y., Mazda O. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res. 2009, 69:2523-2530.
10. Nagai H., Oniki S., Fujiwara S., Xu M., Mizoguchi I., Yoshimoto T., Nishigori C. Antitumor activities of interleukin-27 on melanoma. Endocr., Metab. Immune Disord.: Drug Targets 2010, 10:41-46.
11. Collison L.W., Delgoffe G.M., Guy C.S., Vignali K.M., Chaturvedi V., Fairweather D., Satoskar A.R., Garcia K.C., Hunter C.A., Drake C.G., Murray P.J., Vignali D.A. The composition and signaling of the IL-35 receptor are unconventional. Nat. Immunol. 2012, 13:290-299.
12. Nishino R., Takano A., Oshita H., Ishikawa N., Akiyama H., Ito H., Nakayama H., Miyagi Y., Tsuchiya E., Kohno N., Nakamura Y., Daigo Y. Identification of Epstein-Barr virus-induced gene 3 as a novel serum and tissue biomarker and a therapeutic target for lung cancer. Clin. Cancer Res. 2011, 17:6272-6286.
13. Larousserie F., Bardel E., Pflanz S., Arnulf B., Lome-Maldonado C., Hermine O., Bregeaud L., Perennec M., Brousse N., Kastelein R., Devergne O. Analysis of interleukin-27 (EBI3/p28) expression in Epstein-Barr virus- and human T-cell leukemia virus type 1-associated lymphomas: heterogeneous expression of EBI3 subunit by tumoral cells. Am. J. Pathol. 2005, 166:1217-1228.
14. Gonin J., Larousserie F., Bastard C., Picquenot J.M., Couturier J., Radford-Weiss I., Dietrich C., Brousse N., Vacher-Lavenu M.C., Devergne O. Epstein-Barr virus-induced gene 3 (EBI3): a novel diagnosis marker in Burkitt lymphoma and diffuse large B-cell lymphoma. PLoS One 2011, 6:e24617.
15. Liu L., Meng J., Zhang C., Duan Y., Zhao L., Wang S., Shan B. Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells. Oncol. Rep. 2012, 27:1497-1503.
16. Li Q., Dong Q., Wang E. Rsf-1 is overexpressed in non-small cell lung cancers and regulates cyclinD1 expression and ERK activity. Biochem. Biophys. Res. Commun. 2012, 420:6-10.
17. Kanwar J.R., Kamalapuram S.K., Kanwar R.K. Targeting survivin in cancer: the cell-signalling perspective. Drug Discov. Today 2011, 16:485-494.
18. Stolfi C., Pallone F., Macdonald T.T., Monteleone G. Interleukin-21 in cancer immunotherapy: Friend or foe?. Oncoimmunology 2012, 1:351-354.
19. Hoejberg L., Bastholt L., Schmidt H. Interleukin-6 and melanoma. Melanoma Res. 2012, 22:327-333.
20. Baillat G., Garrouste F., Remacle-Bonnet M., Marvaldi J., Pommier G. Bcl-xL/Bax ratio is altered by IFNgamma in TNFalpha- but not in TRAIL-induced apoptosis in colon cancer cell line. Biochim. Biophys. Acta 2005, 1745:101-110.
21. Schwartz J.L., Shajahan A.N., Clarke R. The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int. J. Breast Cancer 2011, 2011:912102.
22. Zhou Z., Lafleur E.A., Koshkina N.V., Worth L.L., Lester M.S., Kleinerman E.S. Interleukin-12 up-regulates Fas expression in human osteosarcoma and Ewing's sarcoma cells by enhancing its promoter activity. Mol. Cancer Res. 2005, 3:685-691.
23. Ulukaya E., Acilan C., Yilmaz Y. Apoptosis: why and how does it occur in biology?. Cell Biochem. Funct. 2011, 29:468-480.